Skip to content

Study on the anti-inflammatory and immunomodulatory effects of enteral immune nutrients in the chemoradiotherapy of cervical cancer

Study on the anti-inflammatory and immunomodulatory effects of enteral immune nutrients in the chemoradiotherapy of cervical cancer

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093754
Enrollment
Unknown
Registered
2024-12-11
Start date
2023-05-23
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Immunonutrition group:Start taking 250ml of oral immune formula nutritional milk 3 times a day for 5 days before the start of chemotherapy and radiotherapy, and then take 250ml of oral immune formula
Standard nutrition group:Starting from 5 days before self radiotherapy and chemotherapy, follow the same nitrogen and calorie standard nutritional diet as the immune group

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The patient is fully voluntary and has autonomy, having signed the informed consent form for the study 30 days prior to enrollment; (2) The patient is aged >= 18 years and <= 70 years; (3) The patient has pathologically confirmed cervical cancer, which can be squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma, etc., and requires a concurrent chemoradiotherapy treatment plan; (4) The subject must complete the entire radiation therapy process at our hospital; (5) The case data is complete, including height and weight prior to localization; (6) The Eastern Cooperative Oncology Group (ECOG) score is 0-2 points.

Exclusion criteria

Exclusion criteria: (1) Any patient with abnormal bone marrow hyperplasia or other hematopoietic dysfunction; (2) Patients with clinical symptoms or requiring drainage of pleural fluid, ascites, or pericardial effusion (patients who do not require drainage or show no significant increase in fluid accumulation within 3 days of stopping drainage are eligible for inclusion); (3) Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the researcher's opinion, may increase the risks associated with study participation or interfere with the interpretation of research results. (4) Patients with comorbid malignant tumors; (5) Those with poor compliance and unable to participate in the scheduled protocol on time; (6) Other situations deemed unsuitable for inclusion by researchers.

Design outcomes

Primary

MeasureTime frame
radiation enteritis;

Secondary

MeasureTime frame
Immune factors, inflammatory factors;Biochemical indicators;

Countries

China

Contacts

Public ContactCheng Shuxia

Henan Cancer Hospital

wulove.h@163.com+86 136 5371 8356

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026